BIOVAIL DOUBLES PROFIT, FORECASTS GROWTH

Biovail Corp., whose fourth-quarter net income more than doubled, said Thursday it expects earnings growth of about 25 per cent this year, excluding charges. The drug developer expects to earn between $2.30 to $2.40 (U.S.), without charges. At the mid-point, that represents growth of about 25 per cent over 2005.

The Globe and Mail (http://www.theglobeandmail.com/servlet/story/RTGAM.20060323.wbiovail0323/BNStory/Business/home)